HealthEquity (HQY)
(Delayed Data from NSDQ)
$79.56 USD
+2.47 (3.20%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $79.51 -0.05 (-0.06%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$79.56 USD
+2.47 (3.20%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $79.51 -0.05 (-0.06%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Zacks News
Intuitive Surgical (ISRG) Q4 Earnings Top, Margins Expand
by Zacks Equity Research
Intuitive Surgical (ISRG) gains from solid international show in Q4.
NextGen (NXGN) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
NextGen (NXGN) gains from Recurring revenues in Q3, bookings down.
Teladoc (TDOC) Hits 52-Week High: Will Momentum Sustain?
by Sapna Bagaria
Teladoc (TDOC) stock gains from from positive earnings pre-announcement and news to acquire InTouch Health.
Here's Why You Should Add DexCom (DXCM) to Your Portfolio
by Zacks Equity Research
DexCom (DXCM) expects its strong product portfolio to consistently drive top line.
Nevro (NVRO) Gains Ground on Solid Preliminary Q4 Results
by Zacks Equity Research
Higher revenues and upbeat 2020 worldwide revenue outlook benefit Nevro's (NVRO) preliminary Q4 results.
Allscripts Expands Partnership With PIH Health Through 2025
by Zacks Equity Research
Encouraged by its solid EHR prospects, Allscripts (MDRX) expects a surge in its fourth-quarter 2019 bookings.
Inogen (INGN) Announces Preliminary Q4 Results, Slashes View
by Zacks Equity Research
Inogen (INGN) expects direct-to-consumer sales to be its fastest-growing channel in 2020.
ABIOMED (ABMD) Announces Preliminary Q3 Results, Slashes View
by Zacks Equity Research
ABIOMED's (ABMD) Q3 international revenues grew year over year; fiscal 2020 view slashed.
Teladoc to Buy InTouch Health, Expand Reach in Virtual Care
by Zacks Equity Research
Teladoc (TDOC) to acquire InTouch Health and provide virtual health solutions ranging from critical to everyday care.
Here's Why You Should Add Cerner (CERN) to Your Portfolio
by Zacks Equity Research
Cerner (CERN) expects revenues between $1.41 billion and $1.46 billion in the fourth quarter.
Here's Why You Should Hold on to AngioDynamics Stock Now
by Zacks Equity Research
AngioDynamics (ANGO) retains fiscal 2020 view; VA revenues soft in fiscal Q2.
Walgreens Boots (WBA) Q1 Earnings Lag Estimates, Margins Fall
by Zacks Equity Research
Sluggishness in Walgreens Boots' (WBA) Retail Pharmacy International segment and margin contractions put pressure on the bottom line during Q1.
AngioDynamics (ANGO) Q2 Earnings Top, Revenues Lag Estimates
by Zacks Equity Research
AngioDynamics (ANGO) gains from core Oncology business in the fiscal second quarter, reiterates guidance.
Walgreens Boots (WBA) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Higher comparable pharmacy sales and expanded comparable prescription volume are likely to have aided growth in Walgreens Boots' (WBA) Retail Pharmacy USA during the first quarter of fiscal 2020.
Here's Why You Should Hold on to Becton, Dickinson Stock Now
by Zacks Equity Research
Becton, Dickinson (BDX) expects fiscal 2020 revenue growth to be driven by recent product launches.
New Strong Buy Stocks for December 30th
by Tirthankar Chakraborty
Here are 4 stocks added to the Zacks Rank #1 (Strong Buy) List for today:
Top Ranked Momentum Stocks to Buy for December 30th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 30th
ERFSF or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ERFSF vs. HQY: Which Stock Is the Better Value Option?
HMS Holdings Acquires Nebraska-Based Intrado's Accent Unit
by Zacks Equity Research
The latest deal is likely to boost HMS Holdings' (HMSY) Payment Integrity solutions business.
Here's Why You Should Hold on to Masimo (MASI) Stock Now
by Zacks Equity Research
Masimo (MASI) raises revenue and earnings guidance for 2019.
Why HealthEquity (HQY) Could Be an Impressive Growth Stock
by Shivangi Deora
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider HealthEquity (HQY).
Is HealthEquity (HQY) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (HQY) Outperforming Other Medical Stocks This Year?
Masimo (MASI) Expands Partnership with Texas-Based Drager
by Zacks Equity Research
Masimo (MASI) sees a slew of developments in recent times.
Hill-Rom (HRC) Rides on International Growth, New Launches
by Urmimala Biswas
Hill-Rom (HRC) launches RetinaVue 700 Imager, EarlySense and WatchCare in 2019.
LHC Group Expands Partnership With Ochsner Health System
by Zacks Equity Research
LHC Group (LHCG) sees major expansion in partnerships of late.